Revance Therapeutics files for a $86 million IPO

Comment

Shutterstock photo

Revance Therapeutics, a clinical-stage biotech developing enhanced formulations of botulinum toxin (Botox), filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The Newark, CA-based company, which was founded in 1999, plans to list on the NASDAQ under the symbol RVNC. Revance Therapeutics initially filed confidentially on April 19, 2013. Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com